Jemincare, with the help of Orion, will be furthering the development of their non-opioid drug JMKX000623, an inhibitor of a main sodium channel subtype that balances out pain fibres’ stimulation. Orion corporation has partnered up with Jemincare where the former will be responsible for the international development and marketing rights of the non-opioid drug. This drug will treat acute as well as chronic pain. In addition to royalty payments, Orion will also make an upfront payment of $15 million to Jemincare.
Read More from Pharmaceutical Technology